Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2025)

Historic Gross Margin for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to 42.96%.

  • Iovance Biotherapeutics' Gross Margin fell 32100.0% to 42.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.78%, marking a year-over-year decrease of 32100.0%. This contributed to the annual value of 24.43% for FY2024, which is 8289700.0% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Gross Margin stood at 42.96%, which was down 32100.0% from 5.48% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Gross Margin registered a high of 46.17% during Q3 2024, and its lowest value of 915.52% during Q1 2024.
  • In the last 3 years, Iovance Biotherapeutics' Gross Margin had a median value of 0.84% in 2024 and averaged 320.79%.
  • The largest annual percentage gain for Iovance Biotherapeutics' Gross Margin in the last 5 years was 9146800bps (2025), contrasted with its biggest fall of -32100bps (2025).
  • Over the past 3 years, Iovance Biotherapeutics' Gross Margin (Quarter) stood at 805.6% in 2023, then skyrocketed by 101bps to 7.0% in 2024, then surged by 514bps to 42.96% in 2025.
  • Its Gross Margin stands at 42.96% for Q3 2025, versus 5.48% for Q2 2025 and 0.85% for Q1 2025.